Company intelligence / Profile preview

Beijing Shijia Jiu Sheng Yuan Pharmaceutical Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Shijia Jiushengyuan Pharmaceutical Technology is a Chinese pharmaceutical research and development company focused on the discovery and clinical advancement of small molecule therapeutics. The company primarily targets metabolic disorders, with a significant emphasis on treatments for type 2 diabetes and hyperuricemia. Their pipeline includes novel SGLT2 inhibitors and DPP-4 inhibitors, as well as combination therapies designed to improve glycemic control. Based in Beijing, the firm operates as a specialized R&D entity within the domestic Chinese life sciences ecosystem.

Therapeutic areas: RheumatologyMetabolic DisordersEndocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Beijing Shijia Jiu Sheng Yuan Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Shijia Jiu Sheng Yuan Pharmaceutical Technology.

Explore the full profile